东方红医疗创新混合基金(QDII)

Search documents
东方红资产管理江琦: 把握科技成长变化 创新药已是长周期行情
Zhong Guo Zheng Quan Bao· 2025-09-14 20:33
Core Viewpoint - The innovative drug sector is experiencing a significant resurgence, with the Oriental Red Medical Upgrade Fund achieving an annual return of 82.35% as of August 22, 2025, driven by a focus on fundamental changes in the market rather than speculative investments [1][2]. Group 1: Investment Strategy - The Oriental Red Medical Innovation Mixed Fund, managed by Jiang Qi and Gao Yi, emphasizes innovative drugs as a key investment focus, anticipating market differentiation where funds will favor truly innovative companies [2][9]. - Jiang Qi employs a unique industry classification system, dividing the pharmaceutical sector into 18 sub-industries and further refining high-growth areas based on growth potential and technological innovation [3][4]. - The investment approach is guided by two main principles: policy direction and growth rate, with a focus on sectors benefiting from national strategic shifts and those exhibiting a compound annual growth rate of 20% [3][4]. Group 2: Market Trends and Future Outlook - The innovative drug market is expected to see a wave of new products entering clinical stages, with 2026-2027 identified as critical years for the sector's growth, particularly in overseas market submissions [7][8]. - Recent policy measures, such as the introduction of a "commercial insurance innovative drug catalog," are anticipated to enhance the valuation logic for innovative drugs and direct resources toward leading companies with strong commercialization capabilities [8]. - The current market sentiment may lead to a shift in investment focus towards innovative companies with deep value, as the initial excitement subsides and rationality returns to the market [8][9].